Statin Combined with Amlodipine Treats Primary Aldosteronism
Recruiting · NCT06523465 · Interventional (participants receive a specific treatment) · Lead sponsor: Third Military Medical University
View the official record on ClinicalTrials.gov →Interventions studied
Amlodipine besylate combined SpironolactoneSimvastatin combined with Amlodipine besylateSimvastatin combined with Spironolactone and Amlodipine besylate.
What this trial is about
The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.
Who can take part
Age range
18 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Clinical diagnosis of primary aldosteronism
Exclusion criteria
- Allergy to drugs in this study
- Pregnancy
- Severe liver and kidney dysfunction
- Mental illness
Where it is running
1 location listed.
- No. 10 Changjiang River Branch, Yuzhong District，Chongqing, China - Chongqing, Chongqing Municipality, China